Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of Hyperbaric Oxygen Therapy on Clinical Symptoms and Markers of Inflammation and Oxidative Stress in Autistic Children: A Pilot Study
Brief Summary: Autism is a neurodevelopmental disorder that currently affects as many as 1 out of 166 children in the United States. Autism is considered by many to be a permanent condition with little hope for improvement. Treatment for autism is centered on special schooling and behavioral therapy; medical science currently has little to offer.

Recent research has discovered that some autistic individuals have decreased blood flow to the brain, evidence of inflammation in the brain, and increased markers of oxidative stress. Multiple independent single photon emission computed tomography (SPECT) and positron emission tomography (PET) research studies have revealed hypoperfusion to several areas of the autistic brain, most notably the temporal regions and areas specifically related to language comprehension and auditory processing. Several studies show that diminished blood flow to these areas correlates with many of the clinical features associated with autism including repetitive, self-stimulatory and stereotypical behaviors, and impairments in communication, sensory perception, and social interaction. Hyperbaric oxygen therapy (HBOT) has been used with clinical success in several cerebral hypoperfusion syndromes including cerebral palsy, fetal alcohol syndrome, closed head injury, and stroke. HBOT can compensate for decreased blood flow by increasing the oxygen content of plasma and body tissues and can even normalize oxygen levels in ischemic tissue. In addition, animal studies have shown that HBOT has potent anti-inflammatory effects and reduces oxidative stress. Furthermore, recent evidence demonstrates that HBOT mobilizes stem cells from human bone marrow which may aid recovery in neurodegenerative diseases. Based upon these findings, it is hypothesized that HBOT will improve symptoms in autistic individuals.

The purpose of this study is to determine if HBOT improves clinical outcomes in children with autism. The study will also determine if HBOT changes markers of inflammation and oxidative stress in autistic children.


Options:
A: Number of Participants With the Given Clinical Global Impression Scale - Improvement (CGI-I) Score (Baseline, 8 Weeks from baseline, and 20 Weeks from baseline)
B: Scores on autism rating scales before and after HBOT; Measure of inflammation before and after HBOT; Measures of oxidative stress before and after HBOT
C: Standardized Measures; In addition to the direct measures of behavior described above, standardized intelligence and adaptive assessments will be conducted prior to the initiation of HBOT. These will include:; ADI/ADOS; WPPSI-III (2-6 years) /WASI (6+ years); Vineland Adaptive Behavior Scale (VABS); Subjective Questionnaires; Aberrant Behavior Checklist; Clinical Global Impression; ATEC; Selected sections of the APEQ; BRIEF; Parenting Stress Index; Repetitive Behavior Scale; A side effect questionnaire; Thoughtful House Caregiver diary
D: Blinded Therapist Autism Diagnostic Observation Schedule (ADOS); Blinded Therapist Aberrant Behavior Checklist (ABC-C); Blinded Physician Clinical Global Impression Severity Score (CGI); Parental Autism Treatment Evaluation Checklist (ATEC)

Answer: B